Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001831942-26-000014·AN2 Therapeutics, Inc.
Schedule 13G ownership disclosure
AN2 Therapeutics, Inc.
Common Stock, par value $0.00001 per share · CUSIP: 037326105
Event date: 2026-03-09
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Commodore Capital LP
Shares: 3,697,435.00 · Class: 9.9%
- Commodore Capital Master LP
Shares: 3,697,435.00 · Class: 9.9%
- Robert Egen Atkinson
Shares: 3,697,435.00 · Class: 9.9%
- Michael Kramarz
Shares: 3,697,435.00 · Class: 9.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001831942-26-000014
- Form type
- SCHEDULE 13G
- Filer
- AN2 Therapeutics, Inc.
- CIK
- CIK 1880438
- Filed
- Mar 16, 2026
- Reporting period
- Mar 09, 2026
- Description
- Schedule 13G beneficial ownership